Richard Law CFA (Goldman Sachs) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Richard Law CFA's stock ratings?

About 46% of Richard's ratings were profitable over a one-year hold, with an average return of +5.1% per rating, measured by 13Foresight from historical prices.

Q: How is Richard ranked?

Richard Law CFA is ranked #1678 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Richard Law CFA

Richard Law CFA

Goldman Sachs

Wall Street Analyst

★★★☆☆

#1678

on 13Foresight · ranked by our own returns

38%

Success Rate

-14.5%

Average Return

9 of 24 calls profitable · -35.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 38% of Richard Law CFA's ratings turned a profit when each position was held for 2 year — averaging -14.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

22 Buy 19 Hold 7 Sell

Richard's Stock Coverage 24 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return
VRDN Viridian Therapeutics	Jun 10, 2026	BUY	Strong Buy +103.7% avg upside 32 analysts	$35.00 110.55% Upside	·
PTGX Protagonist Therapeutics	Jun 10, 2026	HOLD	Strong Buy -22.1% avg upside 19 analysts	$110.00 2.59% Downside	+5.4%
MLYS Mineralys Therapeutics, Inc.	Jun 03, 2026	BUY	Strong Buy +82.7% avg upside 12 analysts	$42.00 70.51% Upside	+0.3%
BCAX Bicara Therapeutics Inc.	Jun 01, 2026	HOLD	Strong Buy +34.1% avg upside 14 analysts	$18.00 22.47% Downside	+11.2%
COAG Hemab Therapeutics Holdings, Inc.	May 26, 2026	BUY	Strong Buy +41.6% avg upside 5 analysts	$36.00 23.07% Upside	·
OLMA Olema Pharmaceuticals	May 12, 2026	BUY	Strong Buy +303.4% avg upside 16 analysts	$23.00 141.92% Upside	-34.2%
MLTX MoonLake Immunotherapeutics	May 11, 2026	SELL	Strong Buy +51.6% avg upside 20 analysts	$12.00 37.59% Downside	-1.9%
CLDX Celldex	May 08, 2026	HOLD	Strong Buy +20.6% avg upside 28 analysts	$38.00 17.25% Upside	-4.7%
RCUS Arcus Biosciences	May 07, 2026	BUY	Strong Buy +38.0% avg upside 20 analysts	$34.00 39.95% Upside	-2.7%
RCKT Rocket Pharmaceuticals	Mar 27, 2026	SELL	Buy +393.7% avg upside 29 analysts	$3.00 10.36% Downside	+21.5%
SLN Silence Therapeutics	Mar 05, 2026	SELL	Strong Buy +372.0% avg upside 9 analysts	$4.00 42.21% Downside	-10.9%
CRNX Crinetics Pharmaceuticals	Mar 01, 2026	BUY	Strong Buy +121.2% avg upside 20 analysts	$67.00 86.88% Upside	-18.1%
ARQT Arcutis Biotherapeutics	Feb 27, 2026	HOLD	Strong Buy +49.6% avg upside 14 analysts	$33.00 25.85% Upside	-4.8%
NUVL Nuvalent	Nov 18, 2025	BUY	Buy -0.3% avg upside 21 analysts	$135.00 9.36% Upside	+18.3%
VKTX Viking Therapeutics	Jul 24, 2025	HOLD	Strong Buy +141.1% avg upside 30 analysts	$33.00 8.60% Upside	-11.5%
QTTB Q32 Bio	Aug 15, 2023	HOLD	Buy +345.2% avg upside 24 analysts	$30.60 157.18% Upside	-90.9%
BEAM Beam Therapeutics	Aug 09, 2023	HOLD	Strong Buy +50.8% avg upside 25 analysts	$47.00 37.72% Upside	-32.5%
CRSP Crispr Therapeutics AG	Aug 08, 2023	HOLD	Buy +39.1% avg upside 41 analysts	$63.00 16.56% Upside	+3.7%
KYMR Kymera Therapeutics	Aug 04, 2023	HOLD	Strong Buy +8.9% avg upside 36 analysts	$37.00 59.00% Downside	+93.4%
NTLA Intellia Therapeutics	Jun 13, 2023	BUY	Buy +151.9% avg upside 37 analysts	$76.00 385.05% Upside	-82.0%
GLUE Monte Rosa Therapeutics	May 12, 2023	HOLD	Strong Buy +27.5% avg upside 14 analysts	$11.00 39.96% Downside	-24.8%
EDIT Editas Medicine	May 05, 2023	HOLD	Buy +407.9% avg upside 33 analysts	$14.00 420.41% Upside	-84.2%
ARVN Arvinas Holding Company	May 05, 2023	BUY	Buy +264.5% avg upside 27 analysts	$61.00 695.23% Upside	-69.8%
CCCC C4 Therapeutics	Feb 24, 2023	HOLD	Strong Buy +330.3% avg upside 19 analysts	$10.00 140.87% Upside	-45.8%

🔒 19 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Richard Law CFA — Frequently Asked Questions

How accurate are Richard Law CFA's stock ratings?

Based on the calls 13Foresight could measure, about 46% of Richard's ratings were profitable over a one-year hold, with an average return of +5.1% per rating, or -8.2% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Richard ranked on 13Foresight?

Richard Law CFA is currently ranked #1678 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Richard cover?

Richard most recently has ratings on VRDN, PTGX, MLYS, BCAX, COAG, OLMA, MLTX, CLDX, RCUS, RCKT, SLN, CRNX and 12 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!